my mhealth

What my mhealth does

my mhealth Limited is a UK-based digital therapeutics company founded in 2012 that operates a population-scale, multi-morbidity digital health platform for long-term conditions. The company sells a portfolio of condition-specific digital therapeutics: myCOPD, myDiabetes, myHeart, and myAsthma, each delivering medication optimization, personalized education, symptom tracking, automated care planning, and digitally enhanced pulmonary and cardiac rehabilitation. The platform architecture uses validated patient-reported outcome measures, health assessments, and Bluetooth-enabled medical device data (Omron, Gluco RX, Agamatrix, Turbu+, Fitbit) via OpenAPI integration to generate personalized evidence-based interventions and condition-specific care plans.

The company monetizes through its Digital Hub subscription model, sold to NHS trusts, Integrated Care Systems (ICSs), and healthcare providers across the UK and Jersey. Distribution is enterprise-led, supported by Digital Health Advisers who assist with clinical pathway transformation and patient on-boarding at scale. The company holds Crown Commercial Service supplier status, ORCHA certification (rating 85), Cyber Essentials certification, Qismet certification, UKCA marking, and has participated in NICE Early Value Assessments, positioning it within formal UK digital therapeutics adoption pathways. Notable customers include NHS Cambridgeshire & Peterborough, Kent & Medway ICB (12,000+ individuals on myDiabetes), Southend University Hospital, NELFT, Mid and South Essex STP, and Jersey Health and Community Services. Beyond the UK, the company operates a US regional variant (myCOPD US) and participates in the Thames Freeport Healthcare Innovation Lab alongside six other healthtech companies.

Name

my mhealth

Legal name

my mhealth Limited

Website

https://mymhealth.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

my mhealth is a UK-based digital therapeutics company that sells a multi-morbidity platform (myCOPD, myDiabetes, myHeart, myAsthma) via subscription to NHS trusts and Integrated Care Systems for population-scale self-management of long-term conditions.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Ambulatory Health Care Services (621), Home Health Care Services (62161), Other Ambulatory Health Care Services (6219), Offices of Physicians (6211)

SIC

Services-Health Services (8000), Services-Home Health Care Services (8082)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industries

Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG), Chronic Disease Management IoT (Diabetes, CHF, COPD, Hypertension) (HLACAPAD), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Chronic Condition Virtual Care & Disease Management (Payer-Sponsored) (HLALACAE)

Keywords

• Digital therapeutics platform
• Chronic disease management
• Pulmonary rehabilitation software
• Multi-morbidity health platform
• NHS digital health

Headquarters

HQ city

Bournemouth

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Digital Hub Subscription: Healthcare providers subscribe to the Digital Hub to distribute the platform to every patient. The subscription model enables unlimited distribution with return on investment from day one. Digital Health Advisers assist with on-boarding and pathway transformation.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

my mhealth develops and sells condition-specific digital therapeutic apps (myCOPD, myDiabetes, myHeart, myAsthma) and digitally enhanced pulmonary and cardiac rehabilitation programmes for the self-management of long-term conditions. These are delivered to NHS trusts, Integrated Care Systems and other healthcare providers through a Digital Hub subscription platform that supports unlimited patient distribution and on-boarding. The platform integrates with Bluetooth medical devices and healthcare systems via OpenAPI to deliver personalised, evidence-based digital interventions.

Product overview

my mhealth offers a multi-morbidity digital health platform providing population-scale digital therapeutics for long-term conditions. The core product portfolio includes myCOPD, myDiabetes, myHeart, and myAsthma as distinct condition-specific apps, each with specialised interventions. Additional offerings include Digitally Enhanced Pulmonary Rehab and Digitally Enhanced Cardiac Rehab modules. The Digital Hub serves as the unified distribution and subscription platform enabling healthcare providers to access and deploy the full suite of digital therapeutics to patients at scale.

Differentiator

Problem solved

Functional benefit

Brands

• Digital Hub: A subscription-based platform enabling healthcare providers to distribute digital therapeutics to every patient, featuring digital health advisers for pathway transformation and patient on-boarding support.
• myCOPD
• myDiabetes
• myHeart
• myAsthma

Products and services

• myCOPD Digital therapeutic app for Chronic Obstructive Pulmonary Disease management, providing self-management tools, medication tracking, exercise videos, pulmonary rehabilitation, symptom tracking, and personalised care plans. Used by NHS trusts and clinicians to support COPD patients at home.
• myDiabetes Digital therapeutic for diabetes self-management offering an alternative to face-to-face education, with digital self-management tools, an educational programme, automated care planning, and evidence-based information and advice. Deployed by NHS diabetes services.
• myHeart Digital therapeutic for heart disease management, including digitally enhanced cardiac rehabilitation delivered to patients in their own homes, increasing healthcare capacity.
• myAsthma Digital therapeutic app for asthma management, deployed at ICS scale by NHS Cambridgeshire & Peterborough to support asthma patients across the region.
• Digitally Enhanced Pulmonary Rehab Evidence-based pulmonary rehabilitation programme delivered digitally to patients in their own homes, increasing the capacity of conventional rehabilitation services for COPD patients.
• Digitally Enhanced Cardiac Rehab Evidence-based cardiac rehabilitation programme delivered digitally to patients in their own homes, increasing the capacity of conventional rehabilitation services for heart disease patients.
• myCOPD US US-specific version of the myCOPD digital therapeutic app, adapted for the American market and available via a dedicated US website.
• Digital Hub Subscription-based distribution platform enabling healthcare providers to distribute the full suite of my mhealth digital therapeutics to every patient, with unlimited access and Digital Health Adviser support for on-boarding at scale.

Quantifiable outcome

• 80% of registered patients become highly engaged active users
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature10 records

Partnerships

Nine partnerships are on record, tiered flagship and core.

• L MarksflagshipStrategic or Co-development Partner · 12 January 2026L Marks, in partnership with Avencera as part of Thames Freeport's delivery consortium, launched an eight-week mobile health screening pilot programme. my mhealth is one of seven healthtech companies integrated in the Thames Freeport Healthcare Innovation Lab, positioning economic zones as testing grounds for health innovation.
• AvenceracoreStrategic or Co-development PartnerAvencera is part of Thames Freeport's delivery consortium leading the Healthcare Innovation Lab with L Marks. my mhealth participates as one of seven healthtech companies in the pilot programme.
• Turbu+coreTechnology or IntegrationIntegration with Turbu+ enables effortless synchronisation of inhaler usage data via selected Bluetooth enabled inhalers.
• OmroncoreTechnology or IntegrationIntegration with Omron enables blood pressure and body composition data transfer from digital monitors and scales to the my mhealth platform.
• Gluco RXcoreTechnology or IntegrationIntegration with Gluco RX simplifies diabetes management with affordable Bluetooth enabled blood glucose meters.
• AgamatrixcoreTechnology or IntegrationIntegration with Agamatrix enables seamless sync of blood glucose readings with the WaveSense JAZZ Blood Glucose Meter.
• FitbitcoreTechnology or IntegrationIntegration with Fitbit enables tracking of physical activity stored in health records to support rehabilitation.
• NHS Cambridgeshire & PeterboroughflagshipStrategic or Co-development PartnerNHS Cambridgeshire & Peterborough has chosen the myAsthma app for widespread deployment across the ICS, representing a major NHS contract win.
• Kent and Medway ICBflagshipStrategic or Co-development PartnerExtended 3-year partnership following successful delivery of myDiabetes across Kent and Medway, with over 12,000 individuals provided access.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vida Health: Virtual care platform delivering chronic-condition (diabetes, hypertension, mental health) coaching to employers and health plans. Matches my mhealth's multi-morbidity platform thesis and B2B payer contracts.
• Omada Health: Digital therapeutics company focused on diabetes, hypertension and related chronic-condition coaching delivered via employer/payer contracts. Closely mirrors my mhealth's payer-sponsored chronic-care DTx model and outcomes-driven contracting.
• Propeller Health (ResMed): Digital respiratory therapeutic for asthma and COPD combining inhaler sensors, patient education and clinician dashboards — a near-direct competitor to myCOPD and myAsthma, including Bluetooth-inhaler partnerships (Turbu+).
• Hinge Health: Large-scale digital therapeutic platform delivering condition-specific musculoskeletal and chronic-care programs to payers and employers. Direct analogue to my mhealth in B2B digital therapeutics sales motion, chronic-condition self-management, and subscription distribution to providers/employers.
• mySugr (Roche): Diabetes self-management app with Bluetooth glucose meter integration and patient-reported outcomes — closely resembles my mhealth's myDiabetes + Gluco RX/Agamatrix integration stack.
• WellDoc: Pioneer in diabetes digital therapeutics with FDA-cleared clinical decision support. Comparable to my mhealth's myDiabetes product in clinical-evidence-led deployment to healthcare providers and integrated coaching.

Regional players

• Liva Healthcare: European digital chronic-condition coaching platform commissioned by NHS and insurers for diabetes, obesity and CVD prevention — overlaps with myHeart, myDiabetes and NHS-contract distribution model.
• Oviva: Europe-headquartered digital health provider delivering NHS- and insurer-funded lifestyle, diabetes and weight-management programs. Comparable in being a DTx sold via UK/NHS commissioning routes with outcomes-based contracts.

Broad incumbents

• Babylon Health: Larger UK digital health incumbent with NHS GP at Hand and chronic-care virtual services. Overlaps with my mhealth in NHS B2B digital-care delivery, but operates a much broader portfolio.

Emerging players

• Huma (formerly Medopad): UK-headquartered remote patient monitoring and digital health platform partnering with NHS trusts and pharma. Comparable in NHS-anchored, multi-condition remote monitoring model using device data and PROMs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/mymhealthltd
• LinkedInlinkedin.com/company/my-mhealth

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about my mhealth